There’s a new way to kill tumors

by eradicating the immune suppressive nature of the TME

IO Biotech is a Phase 3 company leading the way

About us

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on our T-win® technology platform.

Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Latest news

Encouraging five year clinical data for novel next generation Immuno-Oncology therapy In lung cancer presented at ESMO 2017 Congress

Encouraging five year clinical data for novel next generation Immuno-Oncology therapy In lung cancer presented at ESMO 2017 Congress